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Recently, Gadoxetic acid (Gd-EOB-DTPA; PrimovistⓇ; Bayer 
Schering Pharma), a tissue-specific contrast material, has 
been used for clinical MR imaging. This agent is a biphasic 
hepatobiliary contrast agent because it behaves as both an 
extracellular and a hepatocyte-specifi c agent as it undergoes 
both renal and biliary excretion. Up to 50% of the injected 
dose is taken up into normal hepatocytes due to the pres-
ence of the lipophilic ethoxybenzyl group in its chemical 
structure. As such, dynamic imaging can be performed using 
this agent for the evaluation of hemodynamic perfusion or 
status and for hepatobiliary phase imaging (10 to 20 min-
utes after injection) for the evaluation of functional status. 
Compared to extracellular contrast materials, Gadoxetic 
acid-enhanced magnetic resonance imaging (MRI) provides 
comparable arterial enhancement and prominent venous 
washout of hepatocellular carcinoma (HCC) during dynamic 
imaging. Additional hepatobiliary phase images are useful 
for the detection of small lesions that are not readily visible 
during dynamic imaging. Current evidence and experience 
suggest that Gadoxetic acid-enhanced MRI will improve the 
accuracy of HCC imaging diagnosis by allowing better charac-
terization of hypovascular lesions and better differentiation 
of small arterial enhancing lesions as well as by providing 
improved preoperative staging accuracy. Therefore, with the 
aid of Gadoxetic acid-enhanced MRI, very early HCC will be 
more commonly diagnosed, with patient treatment occurring 
in earlier stages of the disease. (Gut Liver 2011;5:15-21)
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INTRODUCTION
Hepatocellular carcinoma (HCC) is currently considered a cur-
able disease, as long as it is diagnosed early.1 The definition of 
‘early diagnosis’ of HCC can be controversial as curable HCC 
may include lesions with a variety of histologic or clinical crite-
ria. Early HCC, as defined by the International Consensus Group 
for Hepatocellular Neoplasia, is represented by small well-
differentiated HCC of vaguely nodular type2 and is regarded as a 
distinct clinical entity with a high rate of surgical cure.3 Accord-
ing to the Barcelona Clinic Liver Cancer (BCLC) staging classi-
fication, patients with very early stage HCC (single HCC <2 cm, 
Child-Pugh class A, performance status 0) or early stage (single 
HCC or 3 nodules <3 cm, Child-Pugh class A or B, performance 
status 0) may anticipate curative treatments.4 Often, an early 
HCC is defined by eligibility for liver transplantation or curative 
surgical resection (e.g., Milan criteria: a tumor 5 cm or less in 
diameter in patients with single HCCs and no more than three 
tumor nodules, each 3 cm or less in diameter).5,6 No matter how 
‘early’ or ‘curable’ HCC is defined, early diagnosis of HCC can 
be achieved by surveillance of at-risk populations.7 Surveillance 
tests include serologic and radiologic examinations. Serum tu-
mor markers, such as alpha-fetoprotein (AFP) and des-gamma-
carboxy prothrombin (DCP) are commonly used for surveillance, 
but their roles in surveillance are being intensely debated in the 
era of sensitive radiologic tests.8,9
RADIOLOGIC SURVEILLANCE TESTS FOR HCC
1. Ultrasonography
Among radiologic tests, ultrasonography (US) is most widely 
used for surveillance.10 Detection and characterization issues 
for focal lesions should be considered when determining the 
success of US as a surveillance tool. If a lesion is found on US 
examination, the characterization process should follow cur-
rent practice guidelines.10-12 According to these guidelines, new 
lesions that are found in HCC patients with cirrhosis that show 
increased enhancement during the arterial phase and rapid 
washout of enhancement during the late phases of dynamic im-
aging are likely.13-15 However, issues still remain if a lesion is ac-
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tually present, but is not identified. US examination is operator 
dependent, and US sensitivity can be markedly diminished in 
patients who are obese or have underlying cirrhosis, decreasing 
the ability for diagnosis even for expert radiologists. According 
to a meta-analysis of prospective surveillance studies, pooled 
sensitivity of HCC diagnosis by US was 94% for any HCC stage 
and 64% for early HCC defined by the Milan criteria.6 A recent 
report using the data of a hepatitis C antiviral long-term treat-
ment against cirrhosis trial,16 US did not reveal any suspicious 
nodules when performed 6 to 12 months before diagnosis in 14 
(36%) of 39 HCC patients, while the sensitivity of DCP and AFP 
were 74% and 61%, respectively. In a recent report from Santi 
et al.17 that compared semiannual and annual surveillance, HCC 
cases were identified outside of Milan criteria in 30% of semian-
nual and in 42% of annual surveillance groups (Fig. 1).
2. Computed tomography and magnetic resonance imaging 
Therefore, there is a need for a more sensitive and accurate 
imaging modality for surveillance of early HCC diagnosis. The 
use of computed tomography (CT) or magnetic resonance imag-
ing (MRI) for the purpose of HCC surveillance is limited,11,12,18 
as both CT and MRI examinations are expensive and not as 
readily available as US. In addition, CT and MRI also require 
the administration of contrast materials that cause side effects 
in most cases. There is no available data in moderate risk pa-
tients to determine the efficacy of surveillance using CT or MRI, 
although there are many results obtained when CT or MRI are 
used as a diagnostic test in patients with suspected or known 
HCC. According to the Japanese guidelines for the management 
of HCC,11,12 periodic imaging by dynamic CT (by using multi-
detector CT, MDCT) or dynamic MRI is recommended every 6 
to 12 months for patients with hepatitis B or C-related cirrhosis, 
especially if a patient has confounding issues, including obesity 
or rough background liver parenchyma, which make it difficult 
to perform optimal US evaluation.
Unpublished data from my institute has shown that among 
79 patients with HCC who showed negative findings on a previ-
ous CT scan obtained at various intervals, none of the patients 
who were followed within an interval of 1 year presented with 
HCC beyond the early stage, while 7 to 18% of patients who 
were followed at a longer interval were diagnosed with HCC(s) 
beyond the Milan Criteria (Fig. 2). 
MRI provides various advantages for the evaluation of HCCs 
in that MRI offers higher tissue contrast compared to US or CT 
scan, images can be obtained utilizing various scan parameters 
or pulse sequences, and tissue-specific contrast media are avail-
able as well as extracellular contrast materials (ECCM). HCCs 
that are not identified on CT are frequently depicted on MRI and 
Fig. 1. A 48-year-old man with liver cirrhosis who was under ultrasonography (US) surveillance for hepatocellular carcinoma (HCC). (A) A US im-
age obtained six months earlier was interpreted as cirrhosis with multiple regenerative nodules. (B) A US image obtained at the time of diagnosis 
showed a large (5.3 cm) hypoechoic mass in the left lobe of the liver, where no focal lesion was identified on the previous US. Quadriphasic com-
puted tomography demonstrated the typical appearance of a small HCC showing hypoattenuation on the precontrast (C), increased enhancement 
on the arterial phase (D), and washout on the venous (E) and equilibrium (F) phase images.
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some nodules that look hypovascular may show typical arterial 
enhancement on dynamic MRI.19 However, there are still some 
difficulties in the evaluation of patients with suspected HCC us-
ing ECCM-enhanced MRI. Small nodules that show hyperinten-
sity on T1-weighted images and hypointensity on T2-weighted 
images can be evaluated as either low or high-grade dysplastic 
nodules or well-differentiated HCC. Identification of arterial 
hypervascularity is difficult for nodules that show hyperinten-
sity on precontrast T1-weighted images. Washout of contrast 
enhancement, which is considered an important sign for the 
diagnosis of HCC, is frequently missing in HCCs that show obvi-
ous findings in other sequences. Small (<2 cm) arterial enhanc-
ing lesions that present hypervascularity at the arterial phase in 
the absence of hypointensity or washout at the venous phases 
are frequently benign, but some small HCCs also show a similar 
pattern. Detection of small or hypovascular HCC may also be 
difficult using conventional ECCM-enhanced MRI.
GADOXETIC ACID-ENHANCED MRI
Gadoxetic acid disodium or Gadoxetate disodium (Gd-EOB-
DTPA; PrimovistⓇ; Bayer Schering Pharma, Berlin, Germany), 
is a tissue-specific contrast material that has recently become 
available for use in clinical MRIs.20-23 This agent is a biphasic 
hepatobiliary contrast agent because it behaves as both an ex-
tracellular and hepatocyte-specific agent24 as it undergoes both 
renal and biliary excretion. Up to 50% of the Gadoxetic acid 
injected dose is taken up into normal hepatocytes due to the 
lipophilic ethoxybenzyl group in its chemical structure.25 There-
fore, dynamic MR images, as in ECCM-enhanced MRI, can be 
obtained for the evaluation of perfusion or hemodynamic status. 
In addition, hepatobiliary phase images can be obtained that 
maximize the hepatic parenchymal enhancement 10 to 20 min-
utes after injection.24 With Gadoxetic acid-enhanced dynamic 
MRI, HCCs may show comparable arterial enhancement as in 
ECCM-enhanced MRI, but venous washout of HCC can be seen 
more prominently. Additional hepatobiliary phase images are 
useful for the detection of small lesions that are not easily vis-
ible on dynamic imaging. Recently, Ahn et al.23 reported a study 
comparing the diagnostic accuracy between image interpreta-
tion with and without hepatobiliary images for the diagnosis 
of HCC on Gadoxetic acid-enhanced MRI. Their results demon-
strated that hepatobiliary phase images obtained after Gadox-
etic acid-enhanced dynamic MRI may assist in better diagnosis 
of HCC, and thus may help guide treatment planning. In this 
study, two small hypointense nodules found only on hepatobili-
ary phase images were resected and confirmed as early HCC. 
This study also showed that very small (<1 cm) lesions that were 
only depicted on hepatobiliary phase images, but not considered 
as HCC on initial interpretation, were finally confirmed as HCC 
on follow-up examinations.
Current evidence and experience suggests that Gadoxetic 
acid-enhanced MRI will improve the accuracy of early diagnosis 
of HCC by allowing for better differentiation of small arterial 
enhancing lesions (SAEL), better characterization of hypovascu-
lar lesions, and better detection of well-differentiated HCC.25,26 
SAEL that shows arterial hypervascularity at the early phases 
of dynamic imaging without showing typical venous washout 
patterns at the late phases of dynamic imaging has long posed 
problems for the early diagnosis of HCC.27,28 Although most 
SAELs turn out to be benign on subsequent follow-up exami-
nations,29,30 it is also true that small HCCs frequently present 
with the nonspecific appearance of SAELs in early stages.31,32 To 
distinguish a small HCC from a benign SAEL, demonstration of 
hypointensity of the lesion at the late phase of dynamic imaging 
is important.33 However, MR imaging of small HCCs using an 
Fig. 2. A 56-year-old man with liver cirrhosis who was under computed tomography (CT) surveillance for hepatocellular carcinoma. CT images 
obtained at the arterial (A) and venous (B) phases showed no focal lesions in the liver. CT images obtained 8 months after the prior CT examina-
tion showed a small hypervascular nodule (arrow), hypevascularity on the arterial phase (C), and washout on the venous phase (D) images. The le-
sion was treated with transarterial chemoembolization. There has been no evidence of recurrence or progression during a follow-up of more than 
four years.
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extracellular MR contrast agent frequently appear as isointense 
on equilibrium phase images.19,34,35 According to a report by Sun 
et al.26, 95.4% of HCCs demonstrated hypointensity on Gadox-
etic acid-enhanced hepatobiliary phase images, while only 3.7% 
of arterially enhancing pseudolesions showed such a finding (Fig. 
3). 
Gadoxetic acid-enhanced MRI may also play an important 
role in the evaluation of problematic hypovascular nodule le-
sions seen on CT or conventional MRI.25 Some hypoattenuat-
ing lesions that do not clearly show arterial enhancement may 
actually show typical arterial enhancement and washout on 
dynamic and hepatobiliary imaging on Gadoxetate disodium-
enhanced MRI. Many hypoattenuating HCCs depicted on CT 
may also show poor arterial enhancement on conventional 
ECCM-enhanced MRI, and some lesions show hyperintensity on 
precontrast T1-weighted images that preclude the appreciation 
of arterial hypervascularity. For these lesions, demonstration of 
marked hypointensity on Gadoxetic acid-enhanced hepatobili-
ary phase images may enhance confidence for HCC diagnosis 
(Fig. 4).
Improvement of the sensitivity of diagnosis of well-differen-
tiated HCC is also expected in the era of Gadoxetate disodium-
enhanced MRI. Many well-differentiated HCCs show isoat-
tenuation or isovascularity on contrast-enhanced CT or ECCM-
enhanced MRI. Even on Gadoxetic acid-enhanced MRI, these 
lesions may not be depicted on precontrast T1- or T2-weighted 
images or on dynamic imaging. However, some well-differen-
tiated HCCs, especially early HCCs, may demonstrate as clear 
hypointensity on hepatobiliary phase images, allowing the early 
diagnosis of those well-differentiated HCCs presenting with 
atypical features in conventional imaging.
However, there are still problems for the characterization of 
hypointense lesions that are only seen on hepatobiliary phase 
images. Some of these lesions may progress to overt HCC within 
several months, while some lesions take much longer to enlarge 
and manifest other ancillary characteristics for a confident diag-
nosis. On the other hand, there are also some lesions that do not 
change for years. Therefore, diagnosis of all hypointense lesions 
Fig. 3. Characterization of small arterial enhancing lesions using Gadoxetic acid-enhanced magnetic resonance imaging (MRI). (A) Computed 
tomography (CT) images (left column, arterial phase images at different locations; right column, equilibrium phase images at the same location 
as the left image for each image) showed two arterial enhancing lesions (arrows) that did not display clear washout on venous phase images. (B) 
Gadoxetic acid-enhanced arterial (left column) and hepatobiliary phase (right column) images at the same location as the CT images. Both le-
sions showed increased arterial enhancement on the arterial phase MR images similar to the corresponding CT images. However, the upper lesion 
showed isointensity on the hepatobiliary phase images, suggesting a benign, non-tumorous arterial enhancing lesion, whereas the lower lesion 
showed dark intensity on hepatobiliary phase images, suggesting a small hepatocellular carcinoma.
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based only on hepatobiliary phase images should be avoided. 
Identification of ancillary characteristics, such as slightly in-
creased signal intensity on T2-weighted images, formation of 
peritumoral capsules, and presence of nodule-in-nodule pat-
terns, are useful for the correct diagnosis of HCC in these cases.36 
Size criteria may be also important, as many experts believe 
that the 1.5 cm size threshold is useful for the diagnosis of early 
hypovascular HCC when a lesion that is identified in patients 
with chronic liver disease shows hypointensity on hepatobiliary 
phase images but do not present with other ancillary character-
istics (Fig. 5).37 
There are several options for lesions that are seen only on 
hepatobiliary phase images without clear arterial hypervas-
cularity or venous washout. Biopsy is a good diagnostic tool 
when the results are malignant, but is frequently impossible to 
perform for small lesions, especially located in an area of the 
liver that is difficult to approach.38 Resection is an option when 
these lesions are present in patients who have an overt HCC that 
is planned for surgical resection. Information from lesions that 
are resected could be important for the establishment of future 
guidelines for the management of these difficult lesions. Follow-
up or close observation is another practical option. However, 
Fig. 4. Small hepatocellular carcinomas (HCCs) showing hypovascularity on computed tomography (CT) examination. (A) Quadriphasic (pre, arte-
rial, portal, and equilibrium [from left to right]) phase dynamic CT images revealed a small hypoattenuating lesion (arrow) that did not display 
arterial hypervascularity. (B) Gadoxetic acid-enhanced dynamic (pre, arterial, portal, and equilibrium [from left to right]) and hepatobiliary phase 
(far right) images demonstrated marked hypervascularity of this lesion with clear hypointensity on late phase images. Another small HCC (thin ar-
row) that was not seen during the CT examination also showed marked hypervascularity on the arterial phase and hypointensity on hepatobiliary 
phase images.
Fig. 5. A small hepatocellular carcinoma (HCC) shown in a 45-year-old man. (A) A Gadoxetic acid-enhanced hepatobiliary phase image showed 
a small hypointense lesion (arrow) that was not seen on other sequences (not shown). (B) The lesion showed considerable enlargement on the 
follow-up image taken 1.5 years after the first examination. (C) Surgical specimens revealed a well-differentiated HCC.
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lesions can grow faster than expected beyond the early stages 
during this follow-up period when a less sensitive exam, such 
as conventional CT or ECCM-MRI, is alternatively used, al-
though it is common clinical practice pattern. Therefore, the use 
of the same modality that was used for the detection of such a 
lesion (Gadoxetic acid-enhanced MRI in this case) is important, 
although the ideal interval for the follow-up is yet to be deter-
mined. Finally, radiofrequency ablation is sometimes performed 
in clinical practice. However, ablation without definite diagnosis 
may impose psychological issues with the patients and increase 
total healthcare costs. 
SUMMARY AND FUTURE DIRECTIONS
In summary, in the era of Gadoxetic acid-enhanced MRI, 
early diagnosis of HCC will become more common leading to 
patient treatment at earlier stages of the disease. This can be 
attributed to better characterization of small arterial enhancing 
lesions and better detection and characterization of hypovascu-
lar or atypical lesions, especially well-differentiated HCC, that 
frequently manifest ambiguous features on conventional CT or 
MR imaging. For future directions, further studies are necessary 
to determine the clinical effectiveness and cost-effectiveness of 
Gadoxetic acid-enhanced MR imaging for the detection of HCC 
at eary stage. Prospective clinical trials may also be warranted 
to compare the effectiveness of Gadoxetate disodium-enhanced 
MR imaging in comparison with current standard surveillance 
tools.
REFERENCES
1. Sherman M. Optimum imaging for small suspected hepatocellular 
carcinoma. Gut 2010;59:570-571.
2. International Consensus Group for Hepatocellular Neoplasia. 
Pathologic diagnosis of early hepatocellular carcinoma: a report 
of the International Consensus Group for Hepatocellular neoplasia. 
Hepatology 2009;49:658-664.
3. Takayama T, Makuuchi M, Hirohashi S, et al. Early hepatocellular 
carcinoma as an entity with a high rate of surgical cure. Hepatol-
ogy 1998;28:1241-1246.
4. Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints 
of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 
2008;100:698-711.
5. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for 
the treatment of small hepatocellular carcinomas in patients with 
cirrhosis. N Engl J Med 1996;334:693-699.
6. Singal A, Volk ML, Waljee A, et al. Meta-analysis: surveillance 
with ultrasound for early-stage hepatocellular carcinoma in pa-
tients with cirrhosis. Aliment Pharmacol Ther 2009;30:37-47.
7. Lencioni R. Surveillance and early diagnosis of hepatocellular car-
cinoma. Dig Liver Dis 2010;42 Suppl 3:S223-S227.
8. Forner A, Reig M, Bruix J. Alpha-fetoprotein for hepatocellular 
carcinoma diagnosis: the demise of a brilliant star. Gastroenterol-
ogy 2009;137:26-29.
9. Marrero JA, Feng Z. Alpha-fetoprotein in early hepatocellular car-
cinoma. Gastroenterology 2010;138:400-401.
10. Bruix J, Sherman M; Practice Guidelines Committee, American 
Association for the Study of Liver Diseases. Management of hepa-
tocellular carcinoma. Hepatology 2005;42:1208-1236.
11. Makuuchi M, Kokudo N, Arii S, et al. Development of evidence-
based clinical guidelines for the diagnosis and treatment of hepa-
tocellular carcinoma in Japan. Hepatol Res 2008;38:37-51.
12. Kudo M, Okanoue T; Japan Society of Hepatology. Management 
of hepatocellular carcinoma in Japan: consensus-based clinical 
practice manual proposed by the Japan Society of Hepatology. 
Oncology 2007;72 Suppl 1:2-15.
13. Forner A, Vilana R, Ayuso C, et al. Diagnosis of hepatic nodules 
20 mm or smaller in cirrhosis: prospective validation of the non-
invasive diagnostic criteria for hepatocellular carcinoma. Hepatol-
ogy 2008;47:97-104.
14. Leoni S, Piscaglia F, Golfieri R, et al. The impact of vascular and 
nonvascular findings on the noninvasive diagnosis of small hepa-
tocellular carcinoma based on the EASL and AASLD criteria. Am J 
Gastroenterol 2010;105:599-609.
15. Sangiovanni A, Manini MA, Iavarone M, et al. The diagnostic and 
economic impact of contrast imaging techniques in the diagnosis 
of small hepatocellular carcinoma in cirrhosis. Gut 2010;59:638-
644.
16. Lok AS, Sterling RK, Everhart JE, et al. Des-gamma-carboxy pro-
thrombin and alpha-fetoprotein as biomarkers for the early detec-
tion of hepatocellular carcinoma. Gastroenterology 2010;138:493-
502.
17. Santi V, Trevisani F, Gramenzi A, et al. Semiannual surveillance 
is superior to annual surveillance for the detection of early hepa-
tocellular carcinoma and patient survival. J Hepatol 2010;53:291-
297.
18. Federle MP. Use of radiologic techniques to screen for hepatocel-
lular carcinoma. J Clin Gastroenterol 2002;35(5 Suppl 2):S92-S100.
19. Yamashita Y, Mitsuzaki K, Yi T, et al. Small hepatocellular carci-
noma in patients with chronic liver damage: prospective compari-
son of detection with dynamic MR imaging and helical CT of the 
whole liver. Radiology 1996;200:79-84.
20. Ringe KI, Husarik DB, Sirlin CB, Merkle EM. Gadoxetate disodium-
enhanced MRI of the liver: part 1, protocol optimization and le-
sion appearance in the noncirrhotic liver. AJR Am J Roentgenol 
2010;195:13-28.
21. Di Martino M, Marin D, Guerrisi A, et al. Intraindividual compari-
son of gadoxetate disodium-enhanced MR imaging and 64-sec-
tion multidetector CT in the Detection of hepatocellular carcinoma 
in patients with cirrhosis. Radiology 2010;256:806-816.
22. Cruite I, Schroeder M, Merkle EM, Sirlin CB. Gadoxetate disodium-
enhanced MRI of the liver: part 2, protocol optimization and 
lesion appearance in the cirrhotic liver. AJR Am J Roentgenol 
2010;195:29-41.
 Kim MJ: Early Diagnosis of HCC  21
23. Ahn SS, Kim MJ, Lim JS, Hong HS, Chung YE, Choi JY. Added 
value of gadoxetic acid-enhanced hepatobiliary phase MR im-
aging in the diagnosis of hepatocellular carcinoma. Radiology 
2010;255:459-466.
24. Hamm B, Staks T, Mühler A, et al. Phase I clinical evaluation of 
Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, phar-
macokinetics, and MR imaging. Radiology 1995;195:785-792.
25. Motosugi U, Ichikawa T, Sou H, et al. Distinguishing hypervascu-
lar pseudolesions of the liver from hypervascular hepatocellular 
carcinomas with gadoxetic acid-enhanced MR imaging. Radiology 
2010;256:151-158.
26. Sun HY, Lee JM, Shin CI, et al. Gadoxetic acid-enhanced magnetic 
resonance imaging for differentiating small hepatocellular carci-
nomas (< or =2 cm in diameter) from arterial enhancing pseudole-
sions: special emphasis on hepatobiliary phase imaging. Invest 
Radiol 2010;45:96-103.
27. O’Malley ME, Takayama Y, Sherman M, et al. Outcome of small 
(10-20 mm) arterial phase-enhancing nodules seen on triphasic 
liver CT in patients with cirrhosis or chronic liver disease. Am J 
Gastroenterol 2005;100:1523-1528.
28. Jeong YY, Mitchell DG, Kamishima T. Small (<20 mm) enhancing 
hepatic nodules seen on arterial phase MR imaging of the cirrhotic 
liver: clinical implications. AJR Am J Roentgenol 2002;178:1327-
1334.
29. Holland AE, Hecht EM, Hahn WY, et al. Importance of small (< 
or=20-mm) enhancing lesions seen only during the hepatic arte-
rial phase at MR imaging of the cirrhotic liver: evaluation and 
comparison with whole explanted liver. Radiology 2005;237:938-
944.
30. Shimizu A, Ito K, Koike S, Fujita T, Shimizu K, Matsunaga N. Cir-
rhosis or chronic hepatitis: evaluation of small (<or=2-cm) early-
enhancing hepatic lesions with serial contrast-enhanced dynamic 
MR imaging. Radiology 2003;226:550-555.
31. Kim YK, Lee YH, Kwak HS, Kim CS, Han YM. Clinical implication 
of small (<20 mm) enhancing hepatic nodules observed only dur-
ing three-dimensional gadobenate dimeglumine-enhanced hepatic 
arterial-phase MRI of the hepatitis B virus-induced mild cirrhosis. 
Clin Imaging 2008;32:453-459.
32. Park MJ, Kim YS, Lee WJ, Lim HK, Rhim H, Lee J. Outcomes of 
follow-up CT for small (5-10-mm) arterially enhancing nodules in 
the liver and risk factors for developing hepatocellular carcinoma 
in a surveillance population. Eur Radiol 2010;20:2397-2404.
33. Marrero JA, Hussain HK, Nghiem HV, Umar R, Fontana RJ, Lok 
AS. Improving the prediction of hepatocellular carcinoma in cir-
rhotic patients with an arterially-enhancing liver mass. Liver 
Transpl 2005;11:281-289.
34. van den Bos IC, Hussain SM, Dwarkasing RS, et al. MR imaging 
of hepatocellular carcinoma: relationship between lesion size and 
imaging findings, including signal intensity and dynamic en-
hancement patterns. J Magn Reson Imaging 2007;26:1548-1555.
35. Hayashida M, Ito K, Fujita T, et al. Small hepatocellular carci-
nomas in cirrhosis: differences in contrast enhancement effects 
between helical CT and MR imaging during multiphasic dynamic 
imaging. Magn Reson Imaging 2008;26:65-71.
36. Khan AS, Hussain HK, Johnson TD, Weadock WJ, Pelletier SJ, 
Marrero JA. Value of delayed hypointensity and delayed enhanc-
ing rim in magnetic resonance imaging diagnosis of small hepa-
tocellular carcinoma in the cirrhotic liver. J Magn Reson Imaging 
2010;32:360-366.
37. Sakamoto M, Hirohashi S. Natural history and prognosis of ad-
enomatous hyperplasia and early hepatocellular carcinoma: multi-
institutional analysis of 53 nodules followed up for more than 6 
months and 141 patients with single early hepatocellular carcino-
ma treated by surgical resection or percutaneous ethanol injection. 
Jpn J Clin Oncol 1998;28:604-608.
38. Kalinski T, Roessner A. Hepatocellular carcinoma: pathology and 
liver biopsy. Dig Dis 2009;27:102-108.
